| Literature DB >> 16845370 |
Axel Thiefes1, Alexander Wolf, Anneke Doerrie, Guntram A Grassl, Kunihiro Matsumoto, Ingo Autenrieth, Erwin Bohn, Hiroaki Sakurai, Rainer Niedenthal, Klaus Resch, Michael Kracht.
Abstract
The mechanism by which YopP simultaneously inhibits mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB pathways has been elusive. Ectopic expression of YopP inhibits the activity and ubiquitination of a complex consisting of overexpressed TGF-beta-activated kinase 1 (TAK1) and its subunit TAK1-binding protein (TAB)1, but not of MEK kinase 1. YopP, but not the catalytically inactive mutant YopP(C172A), also suppresses basal and interleukin-1-inducible activation of endogenous TAK1, TAB1 and TAB2. YopP does not affect the interaction of TAK1, TAB1 and TAB2 but inhibits autophosphorylation of TAK1 at Thr 187 and phosphorylation of TAB1 at Ser 438. Glutathione S-transferase-tagged YopP (GST-YopP) binds to MAPK kinase (MAPKK)4 and TAB1 but not to TAK1 or TAB2 in vitro. Furthermore, YopP in synergy with a previously described negative regulatory feedback loop inhibits TAK1 by MAPKK6-p38-mediated TAB1 phosphorylation. Taken together, these data strongly suggest that YopP binds to TAB1 and directly inhibits TAK1 activity by affecting constitutive TAK1 and TAB1 ubiquitination that is required for autoactivation of TAK1.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16845370 PMCID: PMC1525148 DOI: 10.1038/sj.embor.7400754
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807